LY3214996
1 product
1 abstract
1 target
Target
ERKAbstract
A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2 ERK1/2, and NF1.Org: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Indiana University Simon Cancer Center and Roudebush VAMC, Department of Hematology/Oncology, IU Simon Comprehensive Cancer Center, Melvin and Bren Simon Cancer Center, Indianapolis, IN,
Product
abemaciclib + LY3214996